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Background: Although the rate of in-hospital ischemic events after myocardial infarction (MI)
has dramatically decreased, long-term residual risk may remain substantial. However, most of
the information on current residual risk is derived from highly selected randomized trials.
Hypothesis: In patients with previous MI and no prior ischemic stroke/transient ischemic attack
(TIA), residual ischemic risk increases over time.
Methods: Using the international Reduction of Atherothrombosis for Continued Health
(REACH) registry, we analyzed baseline characteristics and 4-year follow-up of patients with
previous MI and no history of stroke/TIA to describe annual rates of recurrent ischemic events
globally and by geography. The primary outcome was the composite of cardiovascular death,
MI, or stroke. Multivariate analysis identified risk factors associated with recurrent ischemic
events.
Results: Data from 16 770 patients enrolled at 5587 sites in 44 countries were analyzed. The
rate of the primary outcome increased annually from 4.7% during year 1 to reach a 4-year rate
of 15.1%. Compared with North America, Japan experienced lower ischemic event rates
(P < 0.01), whereas Eastern Europe (P < 0.01) and the Middle East (P = 0.01) experienced
higher ischemic event rates. The presence of congestive heart failure, polyvascular disease, dia-
betes, atrial fibrillation or flutter, and older age were associated with increased residual risk (all
P < 0.01). Statin use was associated with lower ischemic risk (P < 0.01).
Conclusions: In this study, residual ischemic risk after MI accrued progressively up to 4 years
of follow-up, emphasizing the value of intensive secondary prevention strategies to minimize
residual risk.
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1 | INTRODUCTION
During the past decade, the risk of recurrent ischemic events after
acute myocardial infarction (MI) has been dramatically reduced.1 This
reduction has been driven both by the wide use of revascularization
and by improvements in pharmacological treatment, especially antith-
rombotic2,3 and lipid-lowering therapies.4 As the current rate of in-
hospital ischemic events (including cardiovascular mortality) is cur-
rently low,5 registry data show that the vast majority of ischemic
events occur after discharge from the index admission. In an analysis
of the international Global Registry of Acute Coronary Events
(GRACE) registry of acute coronary syndromes (ACS), 5-year post-MI
mortality was approximately 20%, with more than two-thirds of
deaths occurring within 30 days after discharge.6 Reduction of this
long-term residual risk represents one of the main challenges in cur-
rent MI management. Its reduction could be achieved by more inten-
sive antithrombotic and lipid-lowering medications. Therefore, it is
important to precisely characterize long-term ischemic residual risk
after MI. Because most of the existing data stem from the highly
selected populations from randomized clinical trials (RCTs), it is
important to use data from large contemporary international regis-
tries, which are externally validated and whose event rates may be
substantially higher.7
We used the Reduction of Atherothrombosis for Continued
Health (REACH) international registry of atherothrombosis8,9 to char-
acterize the residual 4-year ischemic risk in patients with previous MI
and no prior ischemic stroke/transient ischemic attack (TIA) and
describe the main determinants of residual risk. The choice to exclude
patients with prior stroke or TIA was made a priori because the bal-
ance between risk and benefit of antithrombotic agents in this popu-
lation is specific and deserves a separate analysis.10 Specifically, the
main objectives of the present study were to describe annual rates of
recurrent ischemic events defined as a composite of stroke, MI, or
cardiovascular (CV) death over 4 years, globally and by geographic




The design, methods, and main results of the REACH registry, an
international, prospective, observational study, have been previously
described.8,11 Briefly, from December 2003 to June 2004, REACH
enrolled consecutive outpatients age ≥45 years with established cor-
onary artery disease (CAD), cerebrovascular disease, or peripheral
artery disease (PAD), or with ≥3 atherothrombotic risk factors. Docu-
mented CAD was defined as ≥1 of the following criteria: stable
angina with documented CAD, history of unstable angina with docu-
mented CAD, history of percutaneous coronary intervention, history
of coronary artery bypass graft surgery, or previous MI.
Data were collected centrally using standardized case-report
forms. The initial follow-up period was 2 years; however, centers
were invited to participate in a 2-year extension. Signed informed
consent was obtained from all patients, and the institutional review
board in each country approved the protocol. Only patients with prior
MI and no history of stroke or TIA were included in the present
analysis.
2.2 | Outcomes
Following enrollment, detailed baseline characteristics, treatment, and
outcomes were collected annually. Endpoints were not adjudicated
but were based on physician report at the time of follow-up. Stroke
was verified by either hospital records or a neurology consultation.
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Cardiovascular death was defined as any MI or stroke followed by
death in the next 28 days regardless of the cause, death from pulmo-
nary embolism, heart failure (HF), death following vascular surgery,
following a visceral or limb infarction, or any sudden death unless
proven to be non-CV by autopsy. Polyvascular disease was defined
as atherothrombosis in ≥2 arterial beds (coronary, peripheral, cere-
brovascular) at baseline. Cardiovascular hospitalization was defined as
any hospitalization for unstable angina, TIA, worsening of claudication
related to PAD, surgery, carotid angioplasty or stenting, amputation
affecting lower limbs, peripheral bypass graft, or angioplasty or stent-
ing for PAD.
For the current study, the primary outcome was the composite
of stroke, MI, or CV death. The secondary outcomes included CV
death, MI, and stroke analyzed separately, as well as CV
hospitalization.
2.3 | Statistical Analysis
Patients’ baseline characteristics, medical history, and treatment pat-
terns are presented with descriptive statistics, including frequencies
and percentages for categorical variables and mean and SD for con-
tinuous variables, in the overall study population. Kaplan-Meier esti-
mates were used to assess cumulative incidence rates at each year of
follow-up. Patients from each region of enrollment were also investi-
gated as subgroups. Risks of study outcomes for each region were
estimated by Cox proportional hazards models adjusted for the
REACH risk score predicting CV events,12 after exclusion of the geo-
graphic items of the score.
Multivariate Cox regression models were used to assess the
determinant risk factors for residual CV risk in the study population.
Univariate models were first built to assess the impact of each indi-
vidual variable on CV outcomes. A set of variables was then selected
and introduced in multivariate models according to their statistical
significance in univariate models (P ≤ 0.10), their clinical significance,
and their nonredundancy with other variables in the model.
Data were analyzed overall and by the following geographical
regions: North America (Canada and United States), Latin America
(Brazil, Chile, and Mexico), Western Europe (Austria, Belgium, Finland,
France, Germany, Greece, the Netherlands, Portugal, Spain, Switzer-
land, and the United Kingdom), Eastern Europe (Hungary, Romania,
Russia, and Ukraine), the Middle East (Israel and United Arab Emi-
rates), Asia (China, Taiwan, Hong Kong, Malaysia, Philippines, and
Thailand), and Japan. Japan was analyzed separately from the rest of
Asia due to different timing of enrollment. Data were processed using
the SAS software package version 9.3 (SAS Institute, Inc., Cary, NC).
3 | RESULTS
A total of 65 531 patients were initially enrolled at 5587 centers in
44 countries. Of these, 20 461 had a history of MI, among whom
16 770 (83.3%; 95% confidence interval [CI]: 82.9-83.9) had no his-
tory of stroke or TIA and constituted the study population. Of these,
6666 patients were from North America, 531 were from Latin Amer-
ica, 4703 were from Western Europe, 1795 were from Eastern
Europe, 269 were from the Middle East, 1021 were from Asia, and
957 were from Japan. The proportion of patients with an available 4-
year follow-up in our study cohort was 49.3%, taking into account
the countries that prospectively refused to extend the follow-up over
2 years. There was no suggestion of systematic bias when comparing
the characteristics of subjects with a 4-year follow up vs those with-
out a 4-year follow up (see Supporting Information, Table 1, in the
online version of this article).
3.1 | Baseline Characteristics
Mean age (SD) of the overall population was 67  10 years, and
75.4% were men (Table). Proportions of patients with risks factors
were as follows: diabetes mellitus (DM), 35.6%; hypercholesterolemia,
79.2%; hypertension, 76.4%; current smoker, 51.5%; and obesity,
40.1%. The time since the index MI was <1 year for 22.6% of the
population. Important variations in baseline characteristics were
observed according to geographic region of enrollment (Table).
3.2 | Ischemic Events
3.2.1 | Temporal Trends
The cumulative incidence of CV death, MI, or stroke was 4.7% during
the first year after inclusion in the registry, with a continuous accrual
of approximately 3.5% with each year of follow-up. The 4-year rate
(measured starting at enrollment) of CV death, MI, or stroke in the
overall population was 15.1% (Figure 1). The primary outcome was
driven by each of its components: CV death increased by approxi-
mately 2.2% each year (2.2%, 4.2%, 6.1%, and 8.1% for years
1 through 4, respectively), nonfatal MI by slightly more than 1%
annually (1.8%, 3.1%, 4.2%, and 5.3% for years 1 through 4, respec-
tively), and nonfatal stroke by approximately 1% annually (1.0%,
1.8%, 2.6, and 3.6% by years 1 through 4 after enrollment, respec-
tively). Similarly, the cumulative incidence of CV hospitalization also
increased gradually over the 4 years of follow-up, from 11.8% in the
first year to 17.7% in the second year, 23.1% in the third year, and
up to 26.6% by the fourth year (see Supporting Information, Figure 1,
in the online version of this article).
3.2.2 | Differences by Geographic Region
Compared with North America, patients enrolled in Latin America
(hazard ratio [HR]: 0.75, 95% CI: 0.57-1.00, P = 0.04), Western
Europe (HR: 0.85 95% CI: 0.76-0.95, P < 0.01), and Japan (HR: 0.53,
95% CI: 0.41-0.67, P < 0.01) had lower unadjusted rates of 4-year
ischemic events (see Supporting Information, Figure 2, in the online
version of this article). Ischemic event rates were lower in patients
from Japan (HR: 0.52, 95% CI: 0.41-0.67, P < 0.01), whereas patients
in Eastern Europe (HR: 1.17, 95% CI: 1.01-1.36, P < 0.01) and the
Middle East (HR: 1.54, 95% CI: 1.11-2.15, P = 0.01) experienced
more events compared with patients in North America when adjusted
for REACH risk score (Figure 2). Results were similar when adjust-
ments were made for sex and age (see Supporting Information,
Figure 3, in the online version of this article).
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3.2.3 | Risk Factors for Recurrent Ischemic Events
Congestive HF (HR: 1.93, 95% CI: 1.69-2.20, P < 0.01), polyvascular
disease (HR: 1.49, 95% CI: 1.25-1.77, P < 0.01), history of DM (HR:
1.38, 95% CI: 1.22-1.56, P < 0.01), atrial fibrillation (AF) or flutter
(HR: 1.35, 95% CI: 1.14-1.59, P < 0.01) and older age (per additional
year: HR: 1.02, 95% CI: 1.01-1.03, P < 0.01) were associated with
increased risk of ischemic events (Figure 3). Baseline statin use was
significantly associated with a reduction in ischemic events (HR: 0.77,
95% CI: 0.67-0.90, P < 0.01).
4 | DISCUSSION
In this analysis of MI patients from the REACH registry, the residual
ischemic risk increased after the first year after the index event and
TABLE 1 Baseline Patient Demographics and Clinical Characteristics According to Period Since Previous MI
Overall,




















Mean age, y (SD) 67.07 (10.28) 68.93 (10.4) 65.32 (9.86) 66.75 (9.76) 65.32 (9.86) 64.71 (10.47) 62.69 (9.94) 68.32 (9.18)
Male sex (%) 12 638 (75.4) 4621 (69.4) 413 (77.8) 3761 (80.1) 413 (77.8) 214 (80.5) 843 (82.6) 779 (81.4)
DM 5920 (35.6) 2744 (41.3) 202 (38) 1510 (32.5) 202 (38) 127 (47.6) 372 (37.1) 377 (39.6)
HTN 12 806 (76.4) 5508 (82.6) 379 (71.4) 3423 (72.8) 379 (71.4) 197 (73.5) 693 (67.9) 596 (62.3)
Dyslipidemia 13 262 (79.2) 5755 (86.5) 357 (67.2) 3862 (82.2) 357 (67.2) 234 (87) 707 (69.3) 534 (55.8)
Renal impairmenta 331 (2.5) 172 (3.1) 6 (1.6) 54 (1.5) 6 (1.6) 9 (3.8) 40 (5) 21 (2.4)
Angina
Stable 6711 (40.4) 2619 (39.8) 138 (26.1) 1830 (39.1) 138 (26.1) 98 (37.1) 266 (26.3) 308 (32.5)
Unstable 3159 (19.1) 1183 (17.9) 111 (21.1) 828 (17.8) 111 (21.1) 71 (26.7) 202 (20.1) 116 (12.3)
Vascular disease
Single vascular 15 229 (90.8) 6084 (91.3) 501 (94.4) 4076 (86.7) 501 (94.4) 257 (95.5) 986 (96.6) 906 (94.7)
Polyvascular 1541 (9.2) 582 (8.7) 30 (5.6) 627 (13.3) 30 (5.6) 12 (4.5) 35 (3.4) 51 (5.3)
History of MI
≤1 year 3792 (22.6) 1256 (18.8) 153 (28.8) 1040 (22.1) 153 (28.8) 57 (21.2) 363 (35.6) 137 (14.3)
>1 year 12 978 (77.4) 5410 (81.2) 378 (71.2) 3663 (77.9) 378 (71.2) 212 (78.8) 658 (64.4) 820 (85.7)
AF/flutter 1820 (11) 885 (13.5) 36 (6.8) 445 (9.6) 36 (6.8) 17 (6.4) 56 (5.6) 65 (6.8)
CHF 3626 (22) 1660 (25.2) 77 (14.7) 910 (19.7) 77 (14.7) 56 (21.3) 202 (20.3) 157 (16.6)
PAD 1541 (9.2) 582 (8.7) 30 (5.6) 627 (13.3) 30 (5.6) 12 (4.5) 35 (3.4) 51 (5.3)
Obesitya
Overweight (BMI
25– < 30 kg/m2)
7154 (59.8) 2559 (50.4) 271 (71.3) 2258 (64.5) 271 (71.3) 123 (62.4) 403 (84.7) 318 (91.6)
Class I (BMI 30–
> 35 kg/m2)
3322 (27.8) 1548 (30.5) 86 (22.6) 960 (27.4) 86 (22.6) 55 (27.9) 59 (12.4) 26 (7.5)
Class II (BMI 35–
< 40 kg/m2)
1018 (8.5) 606 (11.9) 19 (5) 243 (6.9) 19 (5) 14 (7.1) 8 (1.7) 3 (0.9)
Class III (BMI
≥40 kg/m2)
460 (3.8) 367 (7.2) 4 (1.1) 39 (1.1) 4 (1.1) 5 (2.5) 6 (1.3) 0 (0)
Smoker
Former 8396 (51.5) 3429 (52.6) 290 (55) 2472 (55.2) 290 (55) 95 (37) 422 (41.9) 519 (57.2)
Current 2299 (14.1) 875 (13.4) 45 (8.5) 631 (14.1) 45 (8.5) 35 (13.6) 137 (13.6) 126 (13.9)
Medication
ASA 13 427 (80.2) 5412 (81.3) 467 (87.9) 3618 (77.2) 467 (87.9) 249 (92.6) 802 (78.6) 780 (81.5)
≥1 Antiplatelet 14 770 (88.1) 5726 (86) 506 (95.3) 4176 (88.9) 506 (95.3) 258 (95.9) 938 (91.9) 869 (90.8)
ACEIa 8756 (52.4) 3298 (49.8) 267 (50.5) 2549 (54.4) 267 (50.5) 158 (59.2) 432 (42.3) 274 (28.6)
ARBa 3120 (18.7) 1408 (21.3) 105 (19.9) 749 (16) 105 (19.9) 50 (18.8) 279 (27.4) 295 (30.8)
Nitrate/other
antianginal
6373 (38.5) 2012 (30.8) 157 (30) 1713 (37) 157 (30) 128 (47.9) 531 (52.3) 544 (56.8)
Statin 13 356 (79.7) 5509 (82.8) 397 (74.8) 3973 (84.7) 397 (74.8) 241 (89.6) 754 (73.8) 532 (55.6)
β-Blocker 11 363 (67.9) 4591 (69) 311 (58.8) 3382 (72.2) 311 (58.8) 198 (74.2) 614 (60.1) 333 (34.8)
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid (aspirin);
BMI, body mass index; CHF, congestive heart failure; DM, diabetes mellitus; HTN, hypertension; MI, myocardial infarction; PAD, peripheral artery disease;
REACH, Reduction of Atherothrombosis for Continued Health; SD, standard deviation.
Data are presented as n (%) unless otherwise noted. The percentages are slightly off because the denominator changes dues to missing observations in
some of the variables.
aUnless otherwise indicated, P < 0.001 for all comparisons.
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continuously increased at a yearly rate of approximately 3.5% per
year for 4 years. There was no difference in risk between North
America and Western Europe, but there was a higher risk for Eastern
Europe and the Middle East and a lower risk for Japan. The inde-
pendent predictors of residual risk were increasing age, presence of
polyvascular disease, and history of DM, HF, or AF. The only factor
that was associated with reduced risk was baseline treatment with
statin.
International registries as well as large international randomized
trials consistently showed an increased ischemic risk over the first
year after MI and a slower but continuous accrual of ischemic events
thereafter.2,3,13 In the Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition With Prasugrel–
Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38), major
ischemic events occurred in 10% of the population on prasugrel at
15 months and 9.8% in the ticagrelor group of Platelet Inhibition and
Patient Outcomes (PLATO) at 12 months.2,3 However, these were
RCTs in which patients with ACS experienced more adverse ischemic
events than did stable patients. These trials have to be separated
from secondary prevention trials such as Prevention of Cardiovascu-
lar Events in Patients with Prior Heart Attack Using Ticagrelor Com-
pared With Placebo on a Background of Aspirin (PEGASUS), in which
the ischemic event rate was  9% at 36 months, or the Clopidogrel
for High Atherothrombotic Risk and Ischemic Stabilization, Manage-
ment, and Avoidance (CHARISMA) trial, in which the event rate was
 7% at 30 months.13,14 A recent meta-analysis comparing dual to
single antiplatelet therapy in >33 000 patients for 30 months
showed an event rate of approximately 7%.15 In the Thrombin Recep-
tor Antagonist in Secondary Prevention of Atherothrombotic Ische-
mic Events–Thrombolysis in Myocardial Infarction 50 (TRA 2P-TIMI
50) trial, the rate of the composite endpoint of CV death, MI, or
stroke at 3 years was slightly higher, occurring in 9.7% of patients
with prior MI.16 In comparison, the present analysis from a registry
shows higher event rates than in large randomized trials.13–15,17
These differences can be explained by the nature of our nonrando-
mized cohort, in which there were few selection criteria, and which,
therefore, has probably greater external validity than randomized
trials. Nevertheless, in all studies, event rates increased continuously
over several months of follow-up, emphasizing the importance of the
concept of residual ischemic risk and supporting the potential benefit
of intensified therapies in post-MI patients without history of stroke
or TIA.
Residual ischemic risk was uniformly distributed over the various
geographic areas except for Japan, where patients experienced lower
ischemic event rates, and Eastern Europe and the Middle East, where
ischemic event rates were higher than in North America. The expla-
nations for such differences have been described previously.18
Briefly, differences in management and medication use have been
reported. In addition, gaps in country-based economic organization
and health care systems might explain differences in the prevalence
and management of risk factors. In the end, genetic susceptibilities
FIGURE 1 Cumulative incidence rates of the primary outcome
(CV death, MI, or stroke) for post-MI patients with no history of
TIA/stroke. Abbreviations: CV cardiovascular; MI, myocardial
infarction; TIA, transient ischemic attack.
FIGURE 2 Hazard ratios for the primary outcome of CV death, MI, or stroke in post-MI patients with no history of stroke/TIA according to
geographic region, adjusted for REACH risk score. Abbreviations: CI, confidence interval; CV cardiovascular; HR, hazard ratio; MI, myocardial
infarction; NA, not applicable; REACH, Reduction of Atherothrombosis for Continued Health; Ref., reference; TIA, transient ischemic attack.
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and lifestyle differences may play a role in risk variation.18 Neverthe-
less, residual risk remains high and events accrue progressively over
time across all geographic areas.
The factors associated with increased residual ischemic risk are
consistent with prior observations. Increasing age is one of the
strongest and most robust risk factors for CV events both in pri-
mary19 and secondary prevention.20 An association between AF and
atherothrombotic disease has been described previously, and there is
an important overlap between AF and atherosclerotic populations.21
The presence of both conditions is associated with an increased risk
of death, stroke, ACS, and bleeding.22 This can be explained by the
addition of risk from both conditions and challenges related to phar-
macological treatment among these patients, such as uncertainty as
to the optimal combination of anticoagulation and antiplatelet thera-
pies in this population. That is, antiplatelet therapies do not protect
from AF-related stroke; and the benefit of anticoagulation alone in
protection against coronary events, particularly in MI patients who
have generally undergone coronary stenting for their index MI, is at
best uncertain. This leads to a greater hemorrhagic risk among these
patients.21–23 Heart failure is also an important determinant for CV
events.24,25 Left ventricular systolic dysfunction has been shown to
be linked with higher mortality,26 and chronic HF is a risk factor for
ischemic events, indicating more extensive atherosclerotic disease.27
Likewise, polyvascular disease has been well-documented to be cor-
related with risk in patients with established atherothrombosis.28,29
Several currently available agents can reduce residual ischemic
risk, as we observed that statin therapy was associated with reduced
risk. This observation is consistent with previously reported statin
trials.4,30,31 Further low-density lipoprotein cholesterol (LDL-C)
lowering with ezetimibe has recently demonstrated additional risk
reduction in total CV events when added to statin therapy.32 Other
promising LDL-C–lowering agents are currently being developed that
could further decrease residual risk: PCSK9 inhibitors such as alirocu-
mab and evolocumab,33,34 which have demonstrated reductions in
LDL-C levels when added to statins.35 These trials have suggested a
potential benefit on CV outcomes, but the results of larger, ongoing
outcome trials are needed to determine whether bococizumab is
effective at improving outcomes in high–CV risk patients not at LDL-
C goal with maximally tolerated statin therapy (http://www.
ClinicalTrials.gov: NCT01975376, NCT01975389).36,37 In addition,
other modifiable risk factors include cessation of smoking and reduc-
tion in body mass index to normal, which can lead to better control
of type 2 DM and subsequently reduced CV risk.38
Antithrombotic agents are another option for decreasing residual
risk in atherothrombotic patients. Because patients with previous
stroke or TIA tend to have an unfavorable risk/benefit balance with
newer antiplatelet or anticoagulant agents,10,39 they were excluded
from our study. In the present analysis, use of antiplatelet therapy
was not associated with a reduced risk of ischemic events. However,
because the present analysis focused on patients with CAD, the vast
majority of patients (almost 90%) already received ≥1 antiplatelet
agent. The timing and observational design of this study did not allow
exploration of whether more intensive platelet inhibition (with P2Y12
antagonists such as clopidogrel, ticagrelor, or prasugrel, or with PAR-
1 antagonists such as vorapaxar) or added anticoagulation (with low-
dose factor Xa antagonists such as rivaroxaban) would further reduce
ischemic events, because most of these options were not available at
the time of registry enrollment. However, recent trials of long-term
FIGURE 3 Hazard ratios of determinants for the primary outcome of CV death, nonfatal MI, or nonfatal stroke estimated by multivariate Cox
models in post-MI patients with no history of TIA/stroke. BMI, body mass index; CI, confidence interval; CV, cardiovascular; EU, European
Union; HR, hazard ratio; MI, myocardial infarction; TIA, transient ischemic attack; US, United States.
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antithrombotic therapy, especially after MI or, to a lesser extent,
after percutaneous coronary intervention with drug-eluting
stents, have demonstrated that intensive antithrombotic therapy
used in secondary prevention did reduce the risk of ischemic
events, although at the expense of increased risk of bleed-
ing.13,17,40 In the PEGASUS-TIMI 54 trial, treatment with the
adenosine diphosphate receptor antagonist ticagrelor reduced
the rate of ischemic events compared with placebo in patients
1 to 3 years post-MI.13 Vorapaxar, a PAR-1 platelet receptor
antagonist, has been evaluated in the TRA 2P-TIMI 50 trial in
the setting of secondary prevention in addition to aspirin and/or
clopidogrel17 in patients with stable atherosclerosis defined
by prior MI, stroke, or PAD within the previous 2 weeks to
12 months prior to randomization. The results demonstrated a
reduction in ischemic events at 3 years in patients with prior MI
or PAD. Finally, adjunctive anticoagulation, using Xa inhibition
with low-dose rivaroxaban, in addition to double antiplatelet
therapy with clopidogrel and aspirin, has been shown to reduce
ischemic events in patients with recent ACS.40
4.1 | Study Limitations
Our study has limitations worth noting. These analyses were
drawn from an observational registry; therefore, the results pre-
sented are descriptive, and analyses on the determinants of resid-
ual risk and on geographic differences must be interpreted with
caution. Follow-up rates were high, particularly for a registry of
this scope and size. However, approximately 5.0% of the patients
missed visits and, thus, we cannot actually exclude a small margin
of error in the estimation of event rates; but this would be
expected to result in, if anything, an underestimation of event
rates. Although the registry was global, results may not be gener-
alized to populations not represented by the registry. Moreover,
clinical events were not adjudicated. However, measures were
taken to select high-quality physicians, and hospitals and doctors
provided diagnoses based on their expertise. Finally, the registry
did not capture patient adherence to medication, which could
impact patient outcomes.
5 | CONCLUSION
This analysis of the REACH registry showed residual risk of ischemic
events in patients with previous MI without history of stroke or TIA
continuously increasing by 15.1% over the 4 years of follow-up after
enrollment. This emphasizes the importance of intensive secondary
prevention efforts, including (but not limited to) enhanced antithrom-
botic treatment and more intense lipid lowering, to overcome this
residual risk in selected patients.
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